Abstract
Chromogranins are the major components of the secretory granules of most neuroendocrine cells. Within the secretory pathway, chromogranins are involved in granulogenesis, and in sorting and processing of secretory proteincargo prior to, secretion. Once secreted, they have hormonal, autocrine, and paracrine activities. The chromogranin family includes chromogranins A (CgA) and B (CgB)and secretogranin II (Sgll, once called chromogranin C). The related “granins” NESP55, 7B2, secretogranin III/1B 1075 (SgIII), and secretogranin IV/HISL-19 antigen (SgIV), are also sometimes included when considering the chromogranins. While it is useful to consider the granin proteins as a family with many common features, it is also necessary to examine the distinct features and properties of individual members of the granin family to understand fully their functions, employ them efficiently as tissue, serum, and urinary markers for neuroendocrine neoplasia, and develop an evolutionary-biologic perspective on their contribution to mammalian physiology. Recent advances in chromogranin research include establishing the role of CgA in granulogenesis and the role of CgB in nuclear transcription; new biologic activities for CgA-, CgB-, and SgII-derived peptides; and new marker functions for granins and their proteolytically processed products in endocrine neoplasias
Similar content being viewed by others
References
Banks P, Helle K. The release of protein from the stimulated adrenal medulla. Biochem J 97:40C-41C, 1965.
Kirshner N, Sage HJ, Smith WJ, et al. Release of catecholamines and specific protein from adrenal glands. Science 154:529–531, 1966.
Banks P, Helle KB, Mayor D. Evidence for the presence of a chromogranin-like protein in bovine splenic nerve granules. Mol Pharmacol 5:210–212, 1968.
Blaschko H, Comline RS, Schneider FH, et al. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature 215:58–59, 1967.
Cohn DV, Morrissey JJ, Hamilton JW, et al. Isolation and partial characterization of secretory protein I from bovine parathyroid glands. Biochemistry 20:4135–4140, 1981.
Cohn DV, Zangerle R, Fischer-Colbrie R, et al. Similarity of secretory protein I from parathyroid gland to chromogranin A from adrenal medulla. Proc. Natl Acad Sci USA 79:6056–6059, 1982.
Iacangelo A, Affolter HU, Eiden LE, et al. Bovine chromogranin A sequence and distribution of its messenger RNA in endocrine tissues. Nature 323:82–86, 1986.
O'Connor DT. Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regul Pep 6:263–280, 1983.
Fischer-Colbrie R, Lassmann H, Hagn C, et al. Immunological studies on the distribution of chromogranin A and B in endocrine and nervous tissues. Neuroscience 16:547–555, 1985.
Fischer-Colbrie R, Hagn C, Kilpatrick L, et al. Chromogranin C: a third component of the acidic proteins in chromaffin granules. J Neurochem 47:318–321, 1986.
Rosa P, Hille A, Lee RWH, et al. Secretogranins I and II: two tyrosine-sulfated secretory proteins common to a variety of cells secreting peptides by the regulated pathway. J Cell Biol 101:1999–2011, 1985.
Eiden LE, Huttner WB, Mallet J, et al. A nomenclature proposal for the chromogranin/secretogranin proteins. Neuroscience 21:1019–1021, 1987.
Helle KB, Aunis D, eds. Chromogranins: functional and clinical aspects. New York: Kluwer Academic/Plenum, 2000; 404.
Fischer-Colbrie R, Eder S, Lovisetti-Scamihorn P, et al. Neuroendocrine secretory protein 55: a novel marker for the constitutive secretory pathway. Ann NY Acad Sci 971:317–322, 2002.
Hashimoto S, Fumagalli G, Zanini A, et al. Sorting of three secretory proteins to distinct secretory granules in acidophilic cells of cow anterior pituitary. J Cell Biol 105:1579–1586, 1987.
Natori S, Huttner WB. Chromogranin B (secretogranin I) promotes sorting to the regulated secretory pathway of processing intermediates derived from a peptide hormone precursor. Proc Natl Acad Sci USA 93:4431–4436, 1996.
Jain RK, Joyce PBM, Gorr S-U. Aggregation chaperones enhance aggregation and storage of secretory proteins in endocrine cells. J Biol Chem 275:27,032–27,036, 2000.
Gorr S-U, Jain RK, Kuehn U, et al. Comparative sorting of neuroendocrine secretory proteins: a search for common ground in a mosaic of sorting models and mechanisms. Mol Cell Endocrinol 172:1–6, 2001
Kim T, Tao-Cheng J-H, Eiden LE, et al. Chromogranin A, an “on/off” switch controlling dense-core secretory granule biogenesis. Cell 106:1–13, 2001.
Reiffen FU, Gratzl M. Chromogranins, widespread in endocrine and nervous tissue, bind Ca2+ FEBS Lett 195:327–330, 1986.
Yoo SH, Albanesi JP. High capacity, low affinity Ca2+ binding of chromogranin A. J Biol Chem 266:7740–7745, 1991.
Yoo S-H. pH- and Ca2+-induced conformational change and aggregation of chromogranin B: comparison with chromogranin A and implication in secretory vesicle biogenesis. J Biol Chem 270:12,578–12,583, 1995.
Gerdes H-H, Rosa P, Phillips E, et al. The primary structure of human secretogranin II, a widespread tyrosine-sulfared secretory granule protein that exhibits low pH- and calcium-induced aggregation. J Biol Chem 264:12,009–12,015, 1989.
Hwang JR, Lindberg I. Inactivation of the 7B2 inhibitory CT peptide depends on a cal study of hormone production and chromogranin localization. Am J Pathol 116:464–472, 1984.
Cohn DV, Elting JJ, Frick M, et al. Selective localization of the parathyroid secretory protein-I/adrenal medulla chromogranin A family in a wide variety of endocrine cells of the rat. Endocrinology 114:1963–1974, 1984.
Sankoorikal BJ, Zhu YL, Hodsdon ME, et al. Aggregation of human wild-type and H27A-prolactin in cells and in solution: roles of Zn2+, Cu2+, and pH. Endocrinology 143:1302–1309 2002.
Watanabe T, Uchiyama Y, Grube D. Topology of chromogranin A and secretogranin II in the rat anterior pituitary: potential marker proteins for distinct secretory pathways in gonadotrophs. Histochemistry 96:285–293, 1991.
Sarac MS, Zieske AW, Lindberg I. The lethal form of Cushing's in 7B2 null mice is caused by multiple metabolic and hormonal abnormalities. Endocrinology 143:2324–2332, 2002.
Laurent V, Kimble A, Peng B, et al. Mortality in 7B2 null mice can be rescued by adrenalectomy: involvement of dopamine in ACTH hypersecretion. Proc Natl Acad Sci USA 99:3087–3092, 2002.
Chanat E, Huttner WB. Milieu-induced, selective aggregation of regulated secretory proteins in the trans-Golgi network. J Cell Biol 115:1505–1519, 1991.
Rosa P, Zanini A. Characterization of adenohypophysial polypeptides by two-dimensional gel electrophoresis. II. Sulfated and glycosylated polypeptides. Mol Cell Endocrinol 24:181–193, 1981.
Fischer-Colbrie R, Laslop A, Kirchmair R. Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Prog Neurobiol 46:49–70, 1995.
Settleman J, Nolan J, Angeletti RH. Chromogranin, an integral membrane protein. J Biol Chem 260:1641–1644, 1985.
Pimplikar SW, Huttner WB. Chromogranin B (secretogranin I), a secretory protein of the regulated pathway, is also p9resent in a tightly membrane-associated form in PC12 cells. J Biol Chem 267:4110–4118, 1992.
Yoo SH, So SH, Kweon HS, et al. Coupling of the inositol 1,4,5-trisphosphate receptor and chromogranins A and B in secretory granules. J Biol Chem 275:12,553–12,559, 2000
Yoo SH. Coupling of the IP3 receptor/Ca2+ channel with Ca2+storage proteins chromogranins A and B in secretory granules. Trends Neurosci 23:424–428, 2000.
Iguchi H, Chan JSD, Seidah NG, et al. Tissue distribution and molecular forms of a novel pituitary protein in the rat. Neuroendocrinology 39:453–458, 1984.
Ottiger H-P, Battenberg EF, Tsou A-P, et al. IB1075: a brain-and pituitary-specific mRNA that encodes a novel chromogranin/secretogranin-like component of intracellular vesicles. J Neurosci 10:3135–3147, 1990.
Sichia R, Lovisetti-Scamihorn P, Hogue-Angeletti R, et al. Molecular cloning and characterization of NESP55, a novel chromogranin-like precursor of a peptide with 5-HTIB receptor antagonist activity. J Biol Chem 272:11,657–11,662, 1997.
Fasciotto BH, Gorr S-U, Cohn DV. Autocrine inhibition of parathyroid cell secretion requires proteolytic processing of chromogranin A. Bone Min 17:323–333, 1992.
Egger C, Kirchmair R, Hogue-Angeletti R, et al. Different degrees of processing of secretogranin II in large dense core vesicles of bovine adrenal medulla and sympathetic axons correlate with their content of soluble PC1 and PC2. Neurosci Lett 159:199–201, 1993.
Arden SD, Rutherford NG, Guest PC, et al. The post-translational processing of chromogranin A in the pancreatic islet: involvement of the eukaryote subtilisin PC2. Biochem J 298:521–528, 1994.
Laslop A, Weiss C, Savaria D, et al. Proteolytic processing of chromogranin B and secretogran in II by prohormone convertases. J Neurochem 70:374–383, 1998.
Laslop A, Becker A, Lindberg I, et al. Proteolytic processing of chromogranins is modified in brains of transgenic mice. Ann NY Acad Sci 271:49–52, 2002.
Stridsberg M, Angeletti RH, Helle KB. Characterisation of N-terminal chromogranin A and chromogranin B in mammals by region-specific radioimmunoassays and chromatographic separation methods. J Endocrinol 165:703–714, 2000.
Borch K, Stridsberg M, Burman P, et al. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 32:198–202, 1997.
Kirchmair R, Egger C, Gee P, et al. Differential subcellular distribution of PC1, PC2 and furin in bovine adrenal medulla and secretion of PC1 and PC2 from this tissue. Neurosci Lett 143:143–145, 1992.
Winkler H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49:497–528, 1992.
Metz-Boutigue M-H, Garcia-Sablone P, Hogue-Angeletti R, et al. Intracellular and extracellular processing of chromogranin A: determination of cleavage sites. Eur J Biochem 217:247–257, 1993.
Jiang Q, Yasothornsrikul S, Taupenot L, et al. The local chromaffin cell plasminogen/plasmin system and the regulation of catecholamine secretion. Ann NY Acad Sci 971:445–449, 2002.
Fasciotto BH, Denny JC, Greeley GH Jr, et al. Processing of chromogranin A in the parathyroid: generation of parastatin-related peptides. Peptides 21:1389–1401, 2000.
Seidah NG, Hendy GN, Hamelin J, et al. Chromogranin A can act as a reversible processing enzyme inhibitor: evidence from the inhibition of the IRCM-serine protease 1 cleavage of pro-enkephalin and ACTH at pairs of basic amino acids. FEBS Lett 211:144–150, 1987.
Helle KB, Angeletti RH. Chromogranin A: a multipurpose prohormone? Acta Physiol Scand 152:1–10, 1994.
Iacangelo AL, Eiden LE. Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pep 58:65–88, 1995.
Helle KB, Metz-Boutigie M-H, Aunis D. Chromogranin A as a calcium-binding precusor for a multitude of regulatory peptides for the immune, endocrine and metabolic systems. Curr Med Chem-Immun Endocr Metab Agents 1:119–140, 2001.
Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pep 41:9–18, 1992.
Aardal S, Helle KB, Elsayed S, et al. Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol 5:405–412, 1993.
Angeletti RH, Aardal S, Serck-Hanssen G, et al. Vasoinhibitory activity of synthetic peptides from the amino terminus of chromogranin A. Acta Physiol Scand 152:11–19, 1994.
Sanchez-Margalet V, Gonzalez-Yanes C, Santos-Alvarez J, et al. Pancreastatin: biological effects and mechanisms of action. Adv Exp Med Biol 482:247–262, 2000.
Sanchez-Margalet V, Gonzalez-Yanes C. Pancreastatin inhibits insulin action in rat adipocytes. Am J Physiol 275:E1055-E1060, 1998.
Gonzalez-Yanes C, Sanchez-Margalet V. Pancreastatin modulates insulin signaling in rat adipocytes: mechanisms of cross-talk. Diabetes 49:1288–1294, 2000.
Tatemoto K, Efendic S, Mutt V, et al. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 324:476–478, 1986.
Taupenot L, Ciesielski-Treska J, Ulrich G, et al. Chromogranin A triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells. Neuroscience 72:377–389, 1996.
Sanchez-Margalet V, Lucas M, Goberna R. Pancreastatin action in the liver: dual coupling to different G proteins. Cell Signal 8:9–12, 1996.
Gonzalez-Yanes C, Santos-Alvarez J, Sanchez-Margalet V. Characterization of pancreastatin receptors and signaling in adipocyte membranes. Biochim Biophys Acta 1451: 153–162, 1999.
Schneitler C, Kahler C, Wiedermann CJ, et al. Specific binding of a 1251-secretoneurin analogue to a human monocytic cell line. J Neuroimmunol 86:87–91, 1998.
Lembo PM, Grazzini E, Groblewski T, et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nat Neurosci 5:201–209, 2002.
Rieker S, Fischer-Colbrie R, Eiden L, et al. Phylogenetic distribution of peptides related to chromogranins A and B. J. Neurochem 50:1066–1073, 1988.
Peterson JB, Nelson DL, Ling E, et al. Chromogranin A-like proteins in the secretory granules of a protozoan, Paramecium tetraurelia. J Biol Chem 262:17,264–17,267, 1987.
Brownlee DJA, Fairweather I, Johnston CG, et al. Immunocytochemical demonstration of neuropeptides in the central nervous system of the roundworm, Ascaris suum (Nematoda: Ascaroidea). Parasitology 106:305–316, 1993.
Smart D, Johnston CF, Curry WJ, et al. Immunoreactivity to two specific regions of chromogranin A in the nervous system of Ascaris suum: an immunocytochemical study. Parasitol Res 78:329–335, 1992.
Lindberg I, Tu B, Muller L, et al. Cloning and functional analysis of C. elegans 7B2. DNA Cell Biol 17:727–734, 1998.
Sato F, Kanno T, Nagasawa S, et al. Immunohistochemical localization of chromogranin A in the acinar cells of equine salivary glands contrasts with rodent glands. Cells Tissues Organs 172:29–36, 2002.
Elde R, Haber S, Ho R, et al. Interspecies conservation and variation in peptidergic neurons. Peptides 1:21–26, 1980.
Simon J-P, Aunis D. Biochemistry of the chromogranin A protein family. Biochem J 262:1–13, 1989.
Stridsberg M, Husebye ES. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. Eur J Endocrinol 136:67–73, 1997.
O'Connor DT, Burton D, Deftos LJ. Immunoreactive human chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues. J Clin Endocrinol Metab 57:1084–1086, 1983.
Lloyd RV, Mervak T, Schmide K, et al. Immunohistochemical detection of chromogranin and neuron-specific enolase in pancreatic endocrine neoplasms. Am J Surg Pathol 8:607–614, 1984.
O'Connor DT, Burton DW, Parmer RJ, et al., in Cohn DV et al., eds., Endocrine control of bone and calcium metabolism, Amsterdam: Elsevier, 1984; 187–190.
Lloyd RV, Blaivas M, Wilson BS. Distribution of chromogranin and S100 protein in normal and abnormal adrenal medullamy tissues. Arch Pathol Lab Med 109:633–638, 1985.
Said JW, Vimadalal S, Nash G, et al. Immunoreactive neuron-specific enolase, bombesin, and chromogranin as markers for neuroendocrine lung tumors. Hum Pathol 16:236–240, 1985.
Walts AE, Said JW, Shintaku P, et al. Chromogranin as a marker of neuroendocrine cells in cytologic material—an immunocytochemical study. Am J Clin Pathol 84:273–277, 1985.
O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 314:1145–1151, 1986.
Lloyd RV. Immunohistochemical localization of chromogranin in normal and neoplastic endocrine tissues. Pathol Ann 22:69–90, 1987.
Schmid KW, Fischer-Colbrie R, Hagn C, et al. Chromogranin A and B and secretogranin II in medullary carcinomas of the thyroid. Am J Surg Pathol 11:551–556, 1987.
Schober M, Fischer-Colbrie R, Schmid KW, et al. Comparison of chromogranins A, B, and secretogranin II in human adrenal medulla and pheochromocytoma. Lab Invest 57:385–391, 1987.
Weiler R, Feichtinger H, Schmid KW, et al. Chromogranin A and B and secretogranin II in bronchial and intestinal carcinoids. Virchows Arch A Pathol Anat Histopathol 412:103–109, 1987.
Tischler AS, Dayal Y, Balogh K, et al. The distribution of immunoreactive chromogranins, S-100 protein, and vasoactive intestinal peptide in compound tumors of the adrenal medulla. Hum Pathol 18:909–917, 1987.
Weiler R, Fischer-Colbrie R, Schmid KW, et al. Immunological studies on the occurrence and properties of chromogranin A and B and secretogranin II in endocrine tumors. Am J Surg Pathol 12:877–884, 1988.
Schmid KW, Schröder S, Dockhorn-Dworniczak B, et al. Immunohistochemical demonstration of chromogranin A, chromogranin B, and secretogranin I in extra-adrenal paragangliomas. Modern Pathol 7:347–353, 1994.
Ischia R, Culig Z, Eder U, et al. Presence of chromogranins and regulation of their synthesis and processing in a neuroendocrine prostate tumor cell line. Prostate Suppl 8:80–87, 1998.
Hsiao RJ, Seeger RC, Yu AL, O'Connor DT, Chromogranin A in children with neuroblastoma serum concentration parallels disease stage and predicts survival. J Clin Invest 85:1555–1559, 1990.
Eriksson B, Arnberg H, Oberg K, et al. Chromogranins—new sensitive markers for neuroendocrine tumors. Acta Oncol 28: 325–329, 1989.
Yasuda D, Iguchi H, Funakoshi A, et al. Comparison of plasma pancreastatin and GAWK concentrations, presumed procesing products of chromogranin A and B, in plasma of patients with pancreatic islet cell tumors. Horm Metab Res 25:593–595, 1993.
Iguchi H, Hara N, Hayashi I, etal. Elevation of a novel pituitary protein (7B2) in the palsma in small cell carcinoma of the lung. Eur J Cancer Clin Oncol 25:1225–1232, 1989.
Iguchi H, Niida Y, Natori S, etal. Remarkbble changes in the plasma levels of pituir∢ry protein “7B2” during childhood. Peidatr Res 24:194–196, 1988.
O'Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as ameasure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med 311:764–770, 1984.
Takiyyuddin MA, Brown MR, Dinh TQ, et al. Sympathol-adrenal secretion in humans; factors governing catecholamine and storage vesicle peptide co-release. J Auton Pharmacol 14:187–200, 1994.
Kanno T, Asada N, Yanase H, et al. Salivary secretion of highly concentrated chromogranin a in respone to noradrenaline and acetylcholine in isolated and perfused rat submandibular glands. Exp Physiol 84: 1073–1083, 1999.
Yanaihara N, Kanno T, Asada N, et al. VIP-and PACAP-induced salivary chromogranin A secretion in the isolated perfused submandibular gland of rats. Ann NY Acad Sci 921:218–225, 2000.
Kanno T, Asada N, Yanase H, et al. Salivary secretion of chromogranin A: control by autonomic nervous system. Adv Exp Med Biol 482:143–51, 2000.
Steiner H-J, Weiler R, Ludescher C, et al. Chromogranins A and B are col-localized with atrial natriuretic peptides in secretory granules of rat heart. J Histochem Cytochem 38:845–850, 1990.
Hakanson R, Ding XQ, Norlen P, et al. Circulating pancreastatin is a marker for the enterochromaffin-like cells of the rat stomach. Gastroenterology 108:1445–1452, 1995.
Tateishi K, Funakoshi A, Wakasugi H, et al. Plasma pancreastatin-like immunoreactivity in various diseases. J Clin Endocrinol Metab 69:1305–1308, 1989.
Nielsen E, Welinder BS, Madsen OD. Chromogranin-B, a putative precursor of eight novel rat glucagonoma peptides through procesing at mono-, di-, or tribasic residues. Endocrinology 129:3147–3156, 1991.
Edgren M., Stridsberg M, Kalknar KM, et al. Neuroendocrine markers: chromogranin, pancreastatin and serotonin in the management of patients with advanced renal cell carcinoma. Anticancer Res 16:4871–4874, 1996.
Öberg K. Biology, diagnosis, and treament of neuroendocrine tumors of the gastrointestinal tract. Curr Opin Oncol 6:441–451, 1994.
Falkensammer G, Fischer-Colbrie R, Richter K, et al. Cell-free and cellular synthesi of chromogranin A and B of bovine adrenal medulla. Neuroscience 14:735–746, 1985.
Conn PM, Janovick JA, Braden TD, et al. SIIp: a unique secretogranin/chromogranin of the pituitary released in response to gonadotropin-releasing hormone. Endocrinology 130:3033–3040, 1992.
Hosaka M, Watanabe T, Sakai Y, et al. Identification of a chromogranin A domain that mediates binding to secretogranin II and targeting to secretory granules in pituitary cells and pancreatic beta-cells. Mol Biol Cell 13:3388–3399, 2002.
Neuhold N, Ullrich R. Secretogranin IV immunoreactivity in medullary thyroid carcinoma: an immunohistochemical study of 62 cases. Virchows Arch A Pathol Anat Histopathol 423:85–89, 1993.
Trani E, Giorgi A, Canu N, et al. Isolation and characterization of VGF peptides in rat brain: role of PC1/3 and PC2 in the maturation of VGF precursor. J Neurochem 81:565–574, 2002
Russell J, Gee P, Liu SM, et al. Inhibition of parathyroid hormone secretion by aminoterminal chromogranin peptides. Endocrinology 135:337–342, 1994.
Lazure C, Paquet L, Litthauer D, et al. The ostrich pituitary contains a major peptide homologous to mammalian chromogranin A(1–76). Peptides 11:79–87, 1990.
Hutton JC, Davidson HW, Grimaldi KA, et al. Bisynthesis of β-granin in pancreatic β cells. Biochem J 244:449–456, 1987.
Hutton JC, Davidson HW, Peshvaria M. The mechanism of chromogranin A processing. Nature 325:766, 1987.
Drees BM, Rouse J, Johnson J, et al. Bovine parathyroid glands secrete a 26-kDa N-terminal fragment of chromogranin-A which inhibits parathyroid cell secretion. Endocrinology 129:3381–3387, 1991.
Drees BM, Hamilton JW. Processing of chromogranin A by bovine parathyroid secretory granules: production and secretion of N-terminal fragments. Endocrinology 134:2057–2063, 1994.
Sekiya K, Ghatei MA, Minamino N, et al. Isolation of human pancreastatin fragment containing the active sequence from a glucogonoma. FEBS Lett 228:153–156, 1988.
Schmidt WE, Siegel EG, Kratzin H, et al. Isolation and primary structure of tumorderived peptides related to human pancreastatin and chromogranin A. Proc Natl Acad Sci USA 85:8231–8235, 1988.
Nakano I, Funkaoshi A, Miyasaka K, et al. Isolation and characterization of bovine pancreastatin. Regul Pep 25:207–213, 1989.
Efendic S, Tatemoto K, Mutt V, et al. Pancreastatin and islet hormone release. Proc Natl Acad Sci USA 84:7257–7260, 1987.
Ahren B, Lindskog S, Tatemoto K, et al. Pancreastatin inhibits insulin secretion and stimulates glucagon secretion in mice. Dibetes 37:281–285, 1988.
Ishizuka J, Asada I, Poston GJ, et al. Effect of pancreastatin on pancreatic endocrine and exocrine secretion. Pancres 4:277–281, 1989.
Lewis JJ, Zdon MJ, Adrian TE, et al. Pancreastatin: a novel peptide inhibitor of parietal cell secretion. Surgery 104:1031–1036, 1988.
Lewis JJ, Goldenring JR, Asher VA, et al. Pancreastatin: a novel peptide inhibitor of pariental cell signal tranduction. Biochem Biophys Res Commun 163:667–673, 1989.
Drees BM, Hamilton JW. Pancreastatin and bovine parathyroid cell secretion. Bone Miner 17:335–346, 1992.
Fasciotto BH, Gorr S-U, DeFranco DJ, et al. Pancreastatin, a presumed product of chromogranin-A (secretory protrein-I procesing, inhibitis secretion from procine parathyroid cells in culture. Endocrinology 125:1617–1622, 1989.
Zhang J-X, Fasciotto BH, Darling DS, et al. Pancreastatin, a chromograin A-derived peptide, inhibits transcription of the parathyroid hormone and chromogranin A genes and decreases the stability of the respective mesenger ribonucleic acids in parathyroid cells in culture. Endocrinology 134:1310–1316, 1994.
Funakoshi A, Miyasaka K, Kitani K, et al. Comparative effects of mammalian pancreastatins on the pancreatic exocrine secretion. Jpn J Physiol 39:901–905, 1989.
Sanchez-Margalet V, Goberna R Pancreastatin decreases plasma epinephrine levels in surgical stress in the rat. Peptides 14:797–799, 1993.
Curry WJ, Shaw C, Johnston CF, et al. Isolation and primary structure of a novel chromogranin A-derived peptide, WE-14, from a human midgut carcinoid tumour. FEBS Lett 301:319–321, 1992.
Forsythe P, Curry WJ, Johnston CF, et al. The modulatory effects of WE-14 on histamine release from rat peritoneal mast cells. Inflamm Res 46(Suppl 1):S13, S14, 1997.
Tsigelny I, Mahata SK, Taupenot L, et al. Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a beta-strand/loop/beeta-strand structure secured by hydrophobic interactions and predictive of activity. Regul Rept 77:43–53, 1998.
Taupenot L, Mahata SK, Mahata M, et al. Interaction of the catecholamine releaseinhibitory peptide catestatin (human chromogranin A(352-372)) with the chromaffin cell surface and Torpedo electroplax: implications for nicotinic cholinergic antagonism. Regul Pept 95:9–17, 2000.
Kennedy BP, Mahata SK, O'Connor DT, et al. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 19:1241–1248, 1998.
Mahata SK, Mahata M, Wakade AR, et al. Primary structure and function of the carecholamine release inhibitory peptide catestatin (chromogranin A344–364): identification of amino acid residues crucial for activity. Mol Endocrinol 14:1525–1535, 2000.
Strub JM, Guomon Y, Lugardon K, et al. Antibacterial activity of glycosylated and phosphorylated chromogranin A-derived peptide 173–194 from bovine adrenal medullary chromaffin granules. J Biol Chem 271:28,533–28,540, 1996.
Funakoshi A, Jimi A, Yasunami Y, et al. Bioactivity of human pancreastatin and its localization in pancreas. Biochem Biophys Res Commun 159:913–918, 1989.
Fasciotto BH, Trauss CA, Greeley GH, Cohn DV. Parastatin (porcine chromogranin A347.419), a novel chromogranin Aderived peptide, inhibits parathyroid cell secretion. Endocrinology 133:461–466, 1993.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feldman, S.A., Eiden, L.E. The chromogranins: Their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia. Endocr Pathol 14, 3–23 (2003). https://doi.org/10.1385/EP:14:1:3
Published:
Issue Date:
DOI: https://doi.org/10.1385/EP:14:1:3